Multicenter phase 2 trial of nivolumab plus ipilimumab for advanced ovarium and endometrial clear cell cancers

Gynecological clear cell cancers are aggressive malignancies with low response rate to chemotherapy. The phase 2 MoST-CIRCUIT trial, at 17 centers in Australia and New Zealand, evaluated the combination of nivolumab and ipilimumab for advanced clear cell ovarian cancer and clear cell endometrial cancer (CCOC/CCEC). In this nonrandomized clinical trial including 24 CCOC patients and 4 CCEC patients, the combination of nivolumab and ipilimumab resulted in an objective response rate of 54% and a 6-month progression-free survival rate of 58%, with all responses being ongoing. The authors conclude that nivolumab plus ipilimumab combination therapy has significant activity in gynecological clear cell cancers.